Premium
P1–047: Consequences of increased β–amyloid levels at different ages in the brain of transgenic mice overexpressing both human acetylcholinesterase and the APPswe mutation
Author(s) -
Mousavi Malahat,
Svedberg Marie,
Unger Christina,
Yu Wen-Feng,
Guan Zhi-Zhong,
Nordberg Agneta
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.422
Subject(s) - endocrinology , hippocampus , genetically modified mouse , medicine , acetylcholinesterase , transgene , chemistry , biology , biochemistry , enzyme , gene
month old TASTPM mice using anti amyloid (peptide 13-27) immunohistochemistry and for -amyloid peptide species using antibodies recognizing -amyloid -40 and -42. Using a range of dilutions from 1mM to 1nM, the staining characteristics of PIB, BSB, SB-13 and FDDNP were compared to immunohistochemically labelled sections. On assessment of staining characteristics all ligands demonstrated plaques and vascular amyloid deposits to a similar level as total and -42 -amyloid immunohistochemistry. At a concentration of 1uM, PIB and BSB clearly demonstrated whole amyloid deposits while SB-13 at a concentration of 10nM and to a greater extent FDDNP at 100nM clearly demonstrated mainly core plaque. BSB was the only ligand to show non-specific staining of elastic fibers in the vasculature down to a concentration of 10 M. These data highlight subtle differences between the ligands with respect to parenchymal and vascular plaque binding in the TASTPM mouse. Whether this reflects preference for specific amyloid species or the influence of the presence of rodent amyloid is the focus of ongoing studies.